Fig. 1.

GC dosing in the TAKT study

(A) Individual GC dose at each time point. (B) Individual GC dose reductions over time. ^aChange from dose at relapse before study entry. ^bBy 10% per week to a minimum of 0.1 mg/kg/day. Data were collected at 12 weeks (day 85), 24 weeks (day 169), 48 weeks (day 337), 72 weeks (day 506) and 96 weeks (day 673) after TCZ administration. If data were unavailable for the specified time point (definition date) but the patient had other visits within the time window, the most recent data (definition date minus 7 days) were used for dose calculations. The GC doses at each time point were calculated according to each patient’s weight at baseline. GC: glucocorticoid; IQR: interquartile range; Q: quartile; TAKT: Takayasu arteritis Treated with Tocilizumab trial; TCZ: tocilizumab.